Melanoma patients with an elevated (>1.07 ng/mL) baseline EPX serum level also showed a significant delay in progression (Supplementary Figure S8a), while the level of EPX serum at C4 had no effect on PFS (Supplementary Figure S8b). The gene discussed is EPX; the disease is melanoma.